Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2018-05-08 |
InflaRX (Germany) |
$62.9 million |
private placement |
|
Inflammatory diseases |
Private placement |
2018-05-07 |
Melinta Therapeutics (USA - CT) |
up to $6.2 million |
grant |
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB - X) (USA - MA) |
Infectious diseases |
Grant |
2018-05-03 |
Synpromics (UK) |
£1.9 million |
grant |
Scottish Enterprise (UK) |
Technology - Services |
Grant |
2018-04-30 |
Sangamo Therapeutics (USA - CA) |
$230 million |
private placement |
|
Rare diseases - Genetic diseases |
Private placement |
2018-04-27 |
Sangamo Therapeutics (USA - CA) |
$8 million |
grant |
California Institute for Regenerative Medicine (CIRM) (USA - CA) |
Rare diseases - Genetic diseases - Hematological diseases |
Grant |
2018-04-27 |
A-Mansia (Belgium) |
€13 million |
series A financing round |
Seventure (France) Fonds Vives II (Belgium) SRIW Life Sciences (Belgium) Nivelinvest (Belgium) Pierre Drion |
Metabolic diseases |
Series A financing round |
2018-04-26 |
Mereo BioPharma (UK) |
|
IPO |
|
Rare diseases - Genetic diseases |
IPO |
2018-04-19 |
Tmunity Therapeutics (USA - PA) |
$135 million |
series A financing round |
Kleiner Perkins (USA) Ping An Ventures (China) Parker Institute for Cancer Immunotherapy (USA - CA) Gilead Sciences, (USA - CA) Be The Match BioTherapies (USA - MN) University of Pennsylvania (USA - PA) Lilly Asia Ventures (China) |
Cancer - Oncology |
Series A financing round |
2018-04-02 |
ITBMed (Sweden) |
up to $67 million |
financing round |
Royalty Pharma (US - NY) |
Transplantation |
Financing round |
2018-03-27 |
Poietis (France) |
€5 million |
series A financing round, grant |
WiSEED (France) Nouvelle Aquitaine Coinvestment Fund (France) |
Technology - Services |
Series A financing round |
2018-03-15 |
Ideaya Bioscience (USA - CA) |
$94 million |
series B financing round |
BVF Partners (USA - CA) Perceptive Advisors (USA - NY) 6 Dimensions Capital (China) Tavistock Group (Bahamas) Nextech Invest (Switzerland) GV (USA - CA) Roche Venture Fund (Switzerland) 5AM Ventures (USA - CA) Canaan Partners (USA - CA) Celgene (USA - NJ) WuXi Healthcare Ventures (China) Novartis Institute of Biomedical Research -Alexandria Real Estate |
Cancer - Oncology |
Series B financing round |
2018-02-23 |
Fate Therapeutics (USA - CA) |
$4 million |
grant |
California Institute for Regenerative Medicine (CIRM) (USA - CA) |
Cancer - Oncology |
Grant |
2018-02-23 |
Fate Therapeutics (USA - CA) |
$4 million |
grant |
California Institute for Regenerative Medicine (CIRM) (USA - CA) |
Cancer - Oncology |
Grant |
2018-02-16 |
ABAC Therapeutics (Spain) |
€16 million |
series A financing round |
Pontifax (Israel) Quark Venture (Canada) GF Securities (China) Caixa Capital Risc (Spain) Debiopharm Innovation Fund (Switzerland) Ferrer (Spain) |
Infectious diseases |
Series A financing round |
2018-02-07 |
Sangamo Therapeutics (USA - CA) Case Western Research University (USA - OH) |
$11 million |
grant |
National Institutes of Health (NIH) (USA) |
Infectious diseases |
Grant |
2018-02-05 |
Metrion Biosciences (UK) |
£200 000 |
grant |
Innovate UK Biomedical Catalyst Feasibility Award scheme (UK) |
Autoimmune diseases - Neurodegenerative diseases |
Grant |
2018-02-02 |
Viking Therapeutics (USA - PA) |
$55 million |
private placement |
|
Endocrinological diseases - Metabolic diseases |
Private placement |
2018-02-02 |
Medivir (Sweden) |
155 million SEK (€ 15.75 million) |
|
|
Infectious diseases |
Private placement |
2018-02-01 |
Avrobio (USA - MA) |
$60 million |
series B financing round |
Cormorant Asset Management and Surveyor Capital (a Citadel company), and included participation by Aisling, Brace Pharma Capital, Eventide Asset Management and Morningside, along with existing investors Atlas Venture, SV Health Investors and Clarus Ventures. |
Cancer - Oncology - Rare diseases - Genetic diseases |
Series B financing round |
2018-01-29 |
Audentes Therapeutics (USA - CA) |
$231.4 million |
private placement |
|
Rare diseases - Genetic diseases |
Private placement |